Anti-inflammatory effects of antidepressants: Possibilities for preventives against alzheimer's disease

Central Nervous System Agents in Medicinal Chemistry

Volumn 9, Issue 1, 2009, Pages 12-19

  Hashioka, Sadayuki ^a   McGeer, Patrick L ^a   Monji, Akira ^b   Kanba, Shigenobu ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Antidepressants; Cytokines; Inflammation; Major depression; Microglia

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CYTOKINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM CHLORIDE; MIRTAZAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CHRONIC INFLAMMATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION REGULATION; GLIA CELL; HUMAN; IMMUNOCOMPETENT CELL; MAJOR DEPRESSION; MICROGLIA; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIOXIDANTS; CELLS, CULTURED; COGNITION DISORDERS; CYTOKINES; DEMENTIA; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; MICROGLIA; NERVE REGENERATION; NEUROGLIA; NEURONS; OXIDATIVE STRESS; PRIONS; STRESS, PSYCHOLOGICAL;

EID: 62549093608     PISSN: 18715249     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152409787601897     Document Type: Review

References (77)

1. Slattery, D.A.; Hudson, A.L.; Nutt, D.J. Invited review: the evolution of antidepressant mechanisms. Fundam. Clin. Pharmacol., 2004, 18 (1), 1-21.
2. Leonard, B.E. Inflammation, depression and dementia: are they connected? Neurochem. Res., 2007, 32 (10), 1749-1756.
3. Yirmiya, R. Endotoxin produces a depressive-like episode in rats. Brain Res., 1996, 711(1-2), 163-174.
4. Kelley, K.W.; Bluthé, R.M.; Dantzer, R.; Zhou, J.H.; Shen, W.H.; Johnson, R.W.; Broussard, S.R. Cytokine-induced sickness behavior. Brain Behav. Immun, 2003, 17 (Suppl 1), S112-S118.
5. Martelli, E.A.; Tóth, E.; Segre, A.D.; Corsico N. Mechanism of inhibition of experimental inflammation by antidepressant drugs. Eur. J. Pharmacol., 1967, 2 (3), 229-233.
6. Mtabaji, J.P.; Manku, M.S.; Horrobin, D.F. Actions of the tricyclic antidepressant clomipramine on responses to pressor agents. Interactions with prostaglandin E2. Prostaglandins, 1977, 14 (1), 125132.
7. Horrobin, D.F. The roles of prostaglandins and prolactin in depression, mania and schizophrenia. Postgrad. Med. J., 1977, 53 (Suppl 4), 160-165.
8. Taler, M.; Gil-Ad, I.; Lomnitski, L.; Korov, I.; Baharav, E.; Bar, M.; Zolokov, A.; Weizman, A. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur. Neuropsychopharmacol., 2007, 17 (12), 774-780.
9. Berk, M.; Wadee, A.A.; Kuschke, R.H.; O'Neill-Kerr, A. Acute phase proteins in major depression. J. Psychosom. Res., 1997, 43 (5), 529-534.
10. Ford, D.E.; Erlinger, T. P. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med., 2004, 164 (9), 1010-1014.
11. Huang, T.L.; Lin, F.C. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31 (2), 370-372.
12. Maes, M. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1995, 19 (1), 11-38.
13. Rothermundt, M.; Arolt, V.; Peters, M.; Gutbrodt, H.; Fenker, J.; Kersting, A.; Kirchner H. Inflammatory markers in major depression and melancholia. J. Affect. Disord., 2001, 63 (1-3), 93-102.
14. Sluzewska, A.; Rybakowski, J; Bosmans, E.; Sobieska, M.; Berghmans, R.; Maes, M.; Wiktorowicz, K. Indicators of immune activation in major depression. Psychiatry Res., 1996, 64 (3), 161-167.
15. Lieb, J.; Karmali, R.; Horrobin, D. Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins Leukot. Med., 1983, 10 (4), 361-367.
16. Calabrese, J.R.; Skwerer, R.G.; Barna, B.; Gulledge, A.D.; Valenzuela, R.; Butkus, A.; Subichin, S.; Krupp, N.E. Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res., 1986, 17 (1), 41-47.
17. Song, C.; Lin, A.; Bonaccorso, S.; Heide, C.; Verkerk, R.; Kenis, G.; Bosmans, E.; Scharpe, S.; Whelan, A.; Cosyns, P.; de Jongh, R.; Maes, M. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J. Affect. Disord., 1998, 49 (3), 211-219.
18. Thomas, A.J.; Davis, S.; Morris, C.; Jackson, E.; Harrison, R.; O'Brien, J.T. Increase in interleukin-1beta in late-life depression. Am. J. Psychiatry, 2005, 162 (1), 175-177.
19. Maes, M.; Meltzer, H.Y.; Bosmans, E.; Bergmans, R.; Vandoolaeghe, E.; Ranjan, R.; Desnyder, R. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord., 1995, 34 (4), 301-309.
20. Motivala, S.J.; Sarfatti, A.; Olmos, L.; Irwin, M.R. Inflammatory markers and sleep disturbance in major depression. Psychosom. Med., 2005, 67 (2), 187-194.
21. Pike, J.L. and Irwin, M.R. Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav. Immun., 2006, 20 (2), 169-174.
22. Penninx, B.W.; Kritchevsky, S.B.; Yaffe, K.; Newman, A.B.; Simonsick, E.M.; Rubin, S.; Ferrucci, L.; Harris, T.; Pahor, M. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol. Psychiatry, 2003, 54 (5), 566-572.
23. Tuglu, C.; Kara, S.H.; Caliyurt, O.; Vardar, E.; Abay, E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl), 2003, 170 (4), 429-433.
24. Myint, A.M.; Leonard, B.E.; Steinbusch, H.W.; Kim, Y.K. Th1, Th2, and Th3 cytokine alterations in major depression. J. Affect. Disord., 2005, 88 (2), 167-173.
25. Levine, J.; Barak, Y.; Chengappa, K.N.; Rapoport, A.; Rebey, M.; Barak, V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology, 1999, 40 (4), 171-176.
26. Carpenter, L.L.; Heninger, G.R.; Malison, R.T.; Tyrka, A.R.; Price, L.H. Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J. Affect. Disord., 2004, 79 (1-3), 285-289.
27. Haack, M.; Hinze-Selch, D.; Fenzel, T.; Kraus, T.; Kühn, M.; Schuld, A.; Pollmächer, T. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J. Psychiatr. Res., 1999, 33 (5), 407-418.
28. Steptoe, A.; Kunz-Ebrecht, S.R.; Owen, N. Lack of association between depressive symptoms and markers of immune and vascular inflammation in middle-aged men and women. Psychol. Med., 2003, 33 (4), 667-674.
29. Müller, N.; Schwarz, M.J.; Dehning, S.; Douhe, A.; Cerovecki, A.; Goldstein-Müller, B.; Spellmann, I.; Hetzel, G.; Maino, K.; Kleindienst, N.; Möller, H.J.; Arolt, V.; Riedel, M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry, 2006, 11 (7), 680-684.
30. Kenis, G.; Maes, M. Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol., 2002, 5 (4), 401-412.
31. Basterzi, A.D.; Aydemir, C.; Kisa, C.; Aksaray, S.; Tuzer, V.; Yazici, K.; Göka, E. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum. Psychopharmacol., 2005, 20 (7), 473-476.
32. O'Brien, S.M.; Scully, P.; Fitzgerald, P.; Scott, L.V.; Dinan, T.G. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res., 2007, 41 (3-4), 326-331.
33. Kubera, M.; Kenis, G.; Bosmans, E.; Zieba, A.; Dudek, D.; Nowak, G.; Maes, M. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol. J. Pharmacol., 2000, 52 (3), 237-241.
34. Kraus, T.; Haack, M.; Schuld, A.; Hinze-Selch, D.; Koethe, D.; Pollmächer, T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry, 2002, 35 (6), 220-225.
35. Kagaya, A.; Kugaya, A.; Takebayashi, M.; Fukue-Saeki, M.; Saeki, T.; Yamawaki, S.; Uchitomi, Y. Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology, 2001, 43 (2), 59-62.
36. Tsao, C.W.; Lin, Y.S.; Chen, C.C.; Bai, C.H.; Wu, S.R. Cytokines and serotonin transporter in patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30 (5), 899-905.
37. Maes, M. The immunoregulatory effects of antidepressants. Hum. Psychopharmacol., 2001, 16 (1), 95-103.
38. Yaron, I.; Shirazi, I.; Judovich, R.; Levartovsky, D.; Caspi, D.; Yaron, M. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum., 1999, 42 (12), 2561-2568.
39. Dantzer, R.; Wollman, E.; Vitkovic, L.; Yirmiya, R. Cytokines and depression: fortuitous or causative association? Mol. Psychiatry, 1999, 4 (4), 328-332.
40. Licinio, J.; Wong, M.L. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry, 1999, 4 (4), 317-327.
41. Obuchowicz, E.; Kowalski, J.; Labuzek, K.; Krysiak, R.; Pendzich, J.; Herman, Z.S. Amitriptyline and nortriptyline inhibit interleukin- 1 release by rat mixed glial and microglial cell cultures. Int. J. Neuropsychopharmacol., 2006, 9 (1), 27-35.
42. Hashioka, S.; Klegeris, A.; Monji, A.; Kato, T.; Sawada, M.; McGeer, P.L.; Kanba, S. Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp. Neurol., 2007, 206 (1), 33-42.
43. Vollmar, P.; Haghikia, A.; Dermietzel, R.; Faustmann, P.M. Venlafaxine exhibits an anti-inflammatory effect in an inflammatory co-culture model. Int. J. Neuropsychopharmacol., 2008, 11 (1), 111-117.
44. Ha, E.; Jung, K.H.; Choe, B.K.; Bae, J.H.; Shin, D.H.; Yim, S.V.; Baik, H.H. Fluoxetine increases the nitric oxide production via nuclear factor kappa B-mediated pathway in BV2 murine microglial cells. Neurosci. Lett., 2006, 397 (3), 185-189.
45. Maes, M.; Song, C.; Lin, A.H.; Bonaccorso, S.; Kenis, G.; De Jongh, R.; Bosmans, E.; Scharpe, S. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology, 1999, 20 (4), 370-379.
46. Uhr, M.; Grauer, M.T.; Holsboer, F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol. Psychiatry, 2003, 54 (8), 840-846.
47. Uhr, M.; Grauer, M.T. Abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J. Psychiatr. Res., 2003, 37 (3), 179-185.
48. Duman, R.S. Novel therapeutic approaches beyond the serotonin receptor. Biol. Psychiatry, 1998, 44 (5), 324-335.
49. Malberg, J.E.; Blendy, J.A. Antidepressant action: to the nucleus and beyond. Trends Pharmacol. Sci., 2005, 26 (12), 631-638.
50. Xia, Z.; DePierre, J.W.; Nassberger, L. Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology, 1996, 34 (1), 27-37.
51. Edgar, V.A.; Sterin-Borda, L.; Cremaschi, G.A.; Genaro, A.M. Role of protein kinase C and cAMP in fluoxetine effects on human T-cell proliferation. Eur. J. Pharmacol., 1999, 372 (1), 65-73.
52. Maes, M.; Kenis, G.; Kubera, M.; De Baets, M.; Steinbusch, H.; Bosmans, E. The negative immunoregulatory effects of fluoxetine in relation to the cAMP-dependent PKA pathway. Int. Immunopharmacol., 2005, 5 (3), 609-618.
53. Delfino, F.; Walker, W.H. Hormonal regulation of the NF-kappaB signaling pathway. Mol. Cell Endocrinol., 1999, 157 (1-2), 1-9.
54. Pahan, K.; Namboodiri, A.M.; Sheikh, F.G.; Smith, B.T.; Singh, I. Increasing cAMP attenuates induction of inducible nitric-oxide synthase in rat primary astrocytes. J. Biol. Chem., 1997, 272 (12), 7786-7791.
55. Ollivier, V.; Parry, G.C.; Cobb, R.R.; de Prost, D.; Mackman, N. Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells. J. Biol. Chem., 1996, 271 (34), 20828-20835.
56. Blanchette, J.; Jaramillo, M.; Olivier, M. Signalling events involved in interferon-gamma-inducible macrophage nitric oxide generation. Immunology, 2003, 108 (4), 513-522.
57. Ma, X.; Chow, J.M.; Gri, G.; Carra, G.; Gerosa, F.; Wolf, S.F.; Dzialo, R.; Trinchieri, G. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J. Exp. Med., 1996, 183 (1), 147-157.
58. Delgado, M. Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression. J. Biol. Chem., 2003, 278 (30), 27620-27629.
59. Wong, M.L.; Whelan, F.; Deloukas, P.; Whittaker, P.; Delgado, M.; Cantor, R.M.; McCann, S.M.; Licinio, J. Phosphodiesterase genes are associated with susceptibility to major depression and antide- pressant treatment response. Proc. Natl. Acad. Sci. USA, 2006, 103 (41), 15124-15129.
60. Kubera, M.; Kenis, G.; Bosmans, E.; Scharpe, S.; Maes, M. Effects of serotonin and serotonergic agonists and antagonists on the production of interferon-gamma and interleukin-10. Neuropsychopharmacology, 2000, 23 (1), 89-98.
61. Deffois, A.; Fage, D.; Carter, C. Inhibition of synaptosomal veratridine-induced sodium influx by antidepressants and neuroleptics used in chronic pain. Neurosci. Lett., 1996, 220 (2), 117-120.
62. Wright, S.L.; Persad, C. Distinguishing between depression and dementia in older persons: neuropsychological and neuropathological correlates. J. Geriatr. Psychiatry Neurol., 2007, 20 (4), 189-198.
63. Klegeris, A.; McGeer, E.G.; McGeer, P.L. Therapeutic approaches to inflammation in neurodegenerative disease. Curr. Opin. Neurol., 2007, 20 (3), 351-357.
64. McGeer, P.L.; McGeer, E.G. Inflammation and the degenerative diseases of aging. Ann. N. Y. Acad. Sci., 2004, 1035, 104-116.
65. Itagaki, S.; McGeer, P.L.; Akiyama, H.; Zhu, S.; Selkoe, D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol., 1989, 24 (3), 173-182.
66. McGeer, P.L.; Itagaki, S.; Tago, H.; McGeer, E.G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett., 1987, 79 (1-2), 195-200.
67. Combs, C.K.; Karlo, J.C.; Kao, S.C.; Landreth, G.E. beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci., 2001, 21 (4), 1179-1188.
68. Hashioka, S.; Monji, A.; Ueda, T.; Kanba, S.; Nakanishi, H. Amyloid-beta fibril formation is not necessarily required for microglial activation by the peptides. Neurochem. Int., 2005, 47 (5), 369-376.
69. Hashioka, S.; Han, Y.H.; Fujii, S.; Kato, T.; Monji, A.; Utsumi, H.; Sawada, M.; Nakanishi, H.; Kanba, S. Phosphatidylserine and phosphatidylcholine- containing liposomes inhibit amyloid beta and interferon-gamma-induced microglial activation. Free Radic. Biol. Med., 2007, 42 (7), 945-954.
70. Meda, L.; Cassatella, M.A.; Szendrei, G.I.; Otvos Jr. L.; Baron, P.; Villalba, M.; Ferrari, D.; Rossi, F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature, 1995, 374 (6523), 647-650.
71. McGeer, P.L.; McGeer, E.G. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol. Aging, 2007, 28 (5), 639-647.
72. Nelson, R.L.; Guo, Z.; Halagappa, V.M.; Pearson, M.; Gray, A.J.; Matsuoka, Y.; Brown, M.; Martin, B.; Iyun, T.; Maudsley, S.; Clark, R.F.; Mattson, M.P. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp. Neurol., 2007, 205 (1), 166-176.
73. Mowla, A.; Mosavinasab, M.; Pani, A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J. Clin. Psychopharmacol, 2007, 27 (1), 67-70.
74. Duman, R.S. Depression: a case of neuronal life and death? Biol. Psychiatry, 2004, 56 (3), 140-145.
75. Malberg, J.E.; Eisch, A.J.; Nestler, E.J.; Duman, R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci., 2000, 20 (24), 9104-9110.
76. Vermetten, E.; Vythilingam, M.; Southwick, S.M.; Charney, D.S.; Bremner, J.D. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol. Psychiatry, 2003, 54 (7), 693-702.
77. Ekdahl, C.T.; Classen, J.H.; Bonde, S.; Kokaia, Z.; Lindvall; O. Inflammation is detrimental for neurogenesis in adult brain. Proc. Natl. Acad. Sci. USA, 2003, 100 (23), 13632-13637.